STADA Arzneimittel AG
http://www.stada.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From STADA Arzneimittel AG
Alvotech And Stada Are Back With A Denosumab Biosimilar Deal
With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.
First-To-Market Calliditas Picking Up Speed In IgA Nephropathy
A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.
Philippines FDA Slashes Approval Timelines For Generic Drugs
The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.
Pentavalent Meningococcal Vaccine Among Latest EU Filings
Marketing applications for MenABCWY, zolbetuximab, crovalimab, macitentan/tadalafil, Coacillium, mRNA-1345, dasiglucagon and ustekinumab have been submitted to the European Medicines Agency for review.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bain Capital
- BIOCEUTICALS Arzneimittel AG
- Britannia Pharmaceuticals Limited
- Cinven
- Forum Bioscience Holdings, Ltd.
- Laboratorio Vannier S.A.
- Nidda Healthcare
- STADAPHARM GmbH
- LobSor Pharmaceuticals AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice